A new retrospective study has analyzed the long-term outcomes of patients originally enrolled in CYCLOPS, in which daily oral (DO) was compared with pulse cyclophosphamide for remission induction in antineutrophil cytoplasmic antibody-associated vasculitis. On the basis of physician records—which included data on relapse, cancer incidence, bone fractures and cardiovascular morbidity—patients who were originally enrolled in the pulse arm had a higher risk of relapse than those in the DO arm, but survival rates did not differ between the two groups (P = 0.92).